Yahoo · Oct 5, 2026
1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Headwinds
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
AO
NYSE · AORT
Artivion, Inc.
Healthcare · Medical - Devices
$21.84
Down-$0.77 (-3.41%)
Updated Oct 7, 2026, 8:39 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.84B
- P/E ratio
- 187.45
- Dividend yield
- 0.00%
- 52-week range
- $19.16 – $39.66
- Volume
- 494.35K
- Avg. volume
- 384.16K
Price performance · AORT
AORT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AORT closed at $21.84 after 21 trading sessions, down 13.09% for the selected period.
- Last close
- $21.84
- Period change
- -13.09%
- Period low
- $21.84
- Period high
- $25.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $22.83 | $23.31 | $21.65 | $21.84 | 494.35K |
| Oct 5, 2026 | $22.21 | $23.04 | $22.16 | $22.61 | 734.22K |
| Oct 2, 2026 | $22.07 | $22.72 | $21.60 | $22.31 | 559.45K |
| Oct 1, 2026 | $22.87 | $23.11 | $21.86 | $21.93 | 501.66K |
| Sep 30, 2026 | $22.91 | $23.105 | $22.64 | $22.82 | 501.37K |
| Sep 29, 2026 | $22.90 | $23.0699 | $22.41 | $22.86 | 336.58K |
| Sep 28, 2026 | $22.63 | $23.205 | $22.415 | $22.95 | 446.06K |
| Sep 25, 2026 | $23.06 | $23.30 | $22.52 | $22.63 | 502.77K |
| Sep 24, 2026 | $23.59 | $23.72 | $23.00 | $23.03 | 567.27K |
| Sep 23, 2026 | $24.15 | $24.76 | $23.03 | $23.53 | 504.22K |
| Sep 22, 2026 | $23.93 | $24.15 | $23.44 | $24.13 | 605.6K |
| Sep 21, 2026 | $23.27 | $23.72 | $22.92 | $23.63 | 569.15K |
| Sep 18, 2026 | $23.80 | $24.255 | $23.30 | $23.35 | 1.91M |
| Sep 17, 2026 | $24.96 | $25.14 | $23.71 | $23.88 | 572.58K |
| Sep 16, 2026 | $25.33 | $25.48 | $24.955 | $25.02 | 683.25K |
| Sep 15, 2026 | $24.89 | $25.75 | $24.40 | $25.38 | 949.01K |
| Sep 14, 2026 | $25.61 | $25.74 | $24.83 | $24.97 | 599.02K |
| Sep 11, 2026 | $24.96 | $25.28 | $24.40 | $25.08 | 547.89K |
| Sep 10, 2026 | $25.12 | $25.40 | $24.5038 | $24.65 | 694.54K |
| Sep 9, 2026 | $25.15 | $25.72 | $24.72 | $25.22 | 553.8K |
| Sep 8, 2026 | $25.42 | $25.81 | $24.915 | $25.13 | 619.37K |
Latest AORT news
The latest Smart Investors Daily articles mentioning AORT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AORT research
Overview
Company profile and research snapshot.
Company profile
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 20, 2026 | Needham | Buy | — |
| Jun 16, 2026 | Canaccord Genuity | Buy | — |
| May 8, 2026 | Citizens | Market Outperform | — |
| May 8, 2026 | Needham | Buy | — |
News briefing
Generated Oct 6, 2026, 9:02 PM
Why Is AORT Down Today?
Artivion, Inc. (AORT) declined 3.41% today, falling $0.77 per share amid broader market positioning. Recent analyst commentary suggests the company faces competitive headwinds despite possessing some structural advantages in its market segments.
Bottom line: Artivion's 3.41% decline appears driven by recent analyst commentary highlighting near-term competitive headwinds, which currently outweigh recognition of the company's structural advantages. While AORT possesses defensible market positions in its segments, investors should monitor execution on key initiatives and any updates on the competitive pressures cited by analysts to determine if this pullback represents a buying opportunity or a sign of deeper challenges ahead.
Yahoo · Sep 25, 2026
2 Growth Stocks with All-Star Potential and 1 We Find Risky
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Yahoo · Sep 23, 2026
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 38.9% gain over the past six months, beating the S&P 500 by 20.9 percentage points.
Yahoo · Sep 16, 2026
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them. Revenue for the quarter ended June 30 climbed 11% on a GAAP basis to $125.8 million, and the company finished assembling what it calls the only complete aortic arch portfolio in its industry. Yet the same […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
